BioPharma Clinical Trials

Antengene And Junshi Biosciences Enter Clinical Collaboration To Advance ATG 037 And JS207 Combination In Solid Tumors

Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, ...

 February 26, 2026 | News

Etherna And Almirall Advance LAD116 mRNA LNP Therapy Into IND Enabling Studies For Non Melanoma Skin Cancer

 etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...

 February 25, 2026 | News

iRegene Advances Global Cell Therapy Programme With Key Parkinson’s And MSA Clinical Milestones

The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical...

 February 25, 2026 | News

Bioxytran Initiates University Of Georgia Collaboration Under 100 Million Dollar Grant To Target H5N1 Bird Flu

Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, announced it has initiated a research c...

 February 24, 2026 | News

CStone Secures UK MHRA Approval For Sugemalimab In Stage III Non Small Cell Lung Cancer

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...

 February 24, 2026 | News

Formosa Pharmaceuticals Signs Exclusive Licensing Agreement With Arrotex For APP13007 In Australia And New Zealand

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...

 February 24, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

–  Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

 February 24, 2026 | News

Hansa Biopharma Announces FDA Acceptance of Imlifidase Biologics License Application

Hansa Biopharma AB, ("Hansa" or "the Company"),  announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. F...

 February 24, 2026 | News

NEXT Life Sciences Advances Two Non Hormonal Male Contraceptives Into Phase II Trials

Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest...

 February 23, 2026 | News

YolTech Reports Positive Interim Data For YOLT 202 In Alpha 1 Antitrypsin Deficiency

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with ...

 February 23, 2026 | News

Takeda Reports Positive Phase 3 KEPLER Data For ENTYVIO In Pediatric Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...

 February 23, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company,  announced a partnership with Accord Healthcare to provide access to ANKTI...

 February 23, 2026 | News

Deciphera Pharmaceuticals Secures FDA NDA Acceptance For Tirabrutinib In R R PCNSL

-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...

 February 20, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

 February 20, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close